Medline Inc. Class A Common Stock (MDLN) - Net Assets
Based on the latest financial reports, Medline Inc. Class A Common Stock (MDLN) has net assets worth $19.29 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.48 Billion) and total liabilities ($19.20 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Medline Inc. Class A Common Stock total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.29 Billion |
| % of Total Assets | 50.11% |
| Annual Growth Rate | 6.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.69 |
Medline Inc. Class A Common Stock - Net Assets Trend (2023–2025)
This chart illustrates how Medline Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Medline Inc. Class A Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Medline Inc. Class A Common Stock (2023–2025)
The table below shows the annual net assets of Medline Inc. Class A Common Stock from 2023 to 2025. For live valuation and market cap data, see how much is Medline Inc. Class A Common Stock worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $19.29 Billion | +16.72% |
| 2024-12-31 | $16.52 Billion | -2.67% |
| 2023-12-31 | $16.98 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medline Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 700000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $27.00 Million | 0.25% |
| Other Components | $10.72 Billion | 99.81% |
| Total Equity | $10.74 Billion | 100.00% |
Medline Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Medline Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PG&E Corp
NYSE:PCG
|
$36.16 Billion |
|
Naspers Limited
F:NNWN
|
$36.18 Billion |
|
Crown Castle
NYSE:CCI
|
$36.18 Billion |
|
Commerzbank AG
XETRA:CBK
|
$36.26 Billion |
|
Keysight Technologies Inc
NYSE:KEYS
|
$35.96 Billion |
|
Interactive Brokers Group Inc
NASDAQ:IBKR
|
$35.85 Billion |
|
CHINA PAC.IN.GR.GDR/5 YC1
F:75CB
|
$35.85 Billion |
|
EMCOR Group Inc
NYSE:EME
|
$35.85 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medline Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,524,000,000 to 10,737,000,000, a change of -5,787,000,000 (-35.0%).
- Net income of 1,159,000,000 contributed positively to equity growth.
- Dividend payments of 518,000,000 reduced retained earnings.
- Share repurchases of 2,003,000,000 reduced equity.
- New share issuances of 7,048,000,000 increased equity.
- Other comprehensive income increased equity by 16,000,000.
- Other factors decreased equity by 11,489,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.16 Billion | +10.79% |
| Dividends Paid | $518.00 Million | -4.82% |
| Share Repurchases | $2.00 Billion | -18.66% |
| Share Issuances | $7.05 Billion | +65.64% |
| Other Comprehensive Income | $16.00 Million | +0.15% |
| Other Changes | $-11.49 Billion | -107.0% |
| Total Change | $- | -35.02% |
Book Value vs Market Value Analysis
This analysis compares Medline Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.07x to 3.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $21.57 | $44.75 | x |
| 2024-12-31 | $20.99 | $44.75 | x |
| 2025-12-31 | $13.22 | $44.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medline Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.79%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.08%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 3.58x
- Recent ROE (10.79%) is above the historical average (6.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 1.38% | 1.01% | 0.64x | 2.13x | $-1.46 Billion |
| 2024 | 7.26% | 4.70% | 0.71x | 2.18x | $-452.40 Million |
| 2025 | 10.79% | 4.08% | 0.74x | 3.58x | $85.30 Million |
Industry Comparison
This section compares Medline Inc. Class A Common Stock's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,863,507,886
- Average return on equity (ROE) among peers: -17.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medline Inc. Class A Common Stock (MDLN) | $19.29 Billion | 1.38% | 1.00x | $35.99 Billion |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $64.44 Million |
| Align Technology Inc (ALGN) | $1.35 Billion | 32.89% | 0.86x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $517.03 Million | -1.36% | 0.37x | $444.32 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $16.74 Million | -22.66% | 1.01x | $1.44 Billion |
| Avinger Inc (AVGR) | $-73.64 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $10.52 Million | -163.15% | 1.04x | $156.14 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $5.43 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $7.87 Billion | 19.65% | 1.00x | $8.85 Billion |
About Medline Inc. Class A Common Stock
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front … Read more